GW Pharmaceuticals PLC Sponsored ADR

( )
GWPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc.
SHPGShire PLC Sponsored ADR
PRGOPerrigo Co. Plc
MNKMallinckrodt Plc
SAGESAGE Therapeutics, Inc.
JAZZJazz Pharmaceuticals Plc
PTLAPortola Pharmaceuticals, Inc.
UTHRUnited Therapeutics Corporation
GWPHGW Pharmaceuticals PLC Sponsored ADR
MDCOMedicines Company
ADMSAdamas Pharmaceuticals, Inc.
ENDPEndo International Plc
ICPTIntercept Pharmaceuticals, Inc.
CORTCorcept Therapeutics Incorporated.

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.